Startseite
Kongressberichte 2019
Annual Meeting of the American Society of Clinical Oncology 2019
Press Briefings
Press Briefing Monday June 3:
Monday June 3 Press Briefing: ASCO Press Releases with links to abstracts
Use of Broader Criteria for Clinical Trial Enrollment Would Double Number of Eligible Patients With Lung Cancer
Conclusions: Use of the ASCO-Friends expanded criteria would enable nearly twice as many aNSCLC pts to be considered for trial participation (4,851 patients, 46.2%). Narrower criteria should only be used based on compelling scientific rationale for exclusion.
| Original cohort | 10,500 (100%) |
|---|---|
| Traditional exclusions | |
| Pts excluded for brain mets | 2,226 (21.2%) |
| Pts excluded for prior/concurrent malignancy | 2,254 (21.5%) |
| Pts excluded for CrCl < 60 mL/min | 1,509 (14.4%) |
| Pts excluded by one of 3 traditional criteria | 5,005 (47.7%) |
| Total pts included by traditional criteria | 5,495 (52.3%) |
| Expanded criteria (Permits brain mets and prior/concurrent malignancy) |
|
| Pts excluded for CrCl < 30 mL/min | 154 (1.5%) |
| Total pts included by ASCO-Friends criteria | 10,346 (98.5%) |
Colorectal Cancer Patients With Liver Metastases Live Just as Long After Laparoscopic Surgery as Open Surgery
The Summary includes updated data, not in the abstract
Conclusions: Laparoscopic surgery in patients with colorectal liver metastases was associated with rates of OS and RFS similar to open surgery. Clinical trial information: NCT01516710
CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT
Novel Targeted-Antibody Treatment Produced Responses in Nearly Half of Patients With Advanced Urothelial Cancer
Conclusions: Preliminary results from this EV pivotal study demonstrated a clinically meaningful ORR, consistent with the phase 1 trial, in la/mUC pts with prior platinum and CPI, including LM pts, where there is a high unmet need. EV was well tolerated with a manageable safety profile in these pts. Updated data, including duration of response, PFS, and OS will be presented. Clinical trial information: NCT03219333
CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT
Over 60 Percent of Gynecologic Oncologists Say They Have Experienced Sexual Harassment
Conclusions: This report is the first to show that experience of sexual harassment is common among Gyn-Onc physicians. Importantly, only a few report these occurrences, often for fear of reprisal or concern that nothing will be done. Further, female Gyn-Oncologists report feeling that gender influences salaries and career advancement. Awareness and acknowledgment of sexual harassment and gender inequalities within Gyn-Onc can lead to interventions to address these disparities.